WO1999005138A1 - Composes heterocycliques et agent antitumoral contenant lesdits composes utilises comme ingredients actifs - Google Patents
Composes heterocycliques et agent antitumoral contenant lesdits composes utilises comme ingredients actifs Download PDFInfo
- Publication number
- WO1999005138A1 WO1999005138A1 PCT/JP1998/003308 JP9803308W WO9905138A1 WO 1999005138 A1 WO1999005138 A1 WO 1999005138A1 JP 9803308 W JP9803308 W JP 9803308W WO 9905138 A1 WO9905138 A1 WO 9905138A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- morpholino
- triazine
- benzimidazole
- tolyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98933922A EP1020462B1 (en) | 1997-07-24 | 1998-07-24 | Heterocyclic compounds and antitumor agent containing the same as active ingredient |
KR1020007000424A KR100563514B1 (ko) | 1997-07-24 | 1998-07-24 | 헤테로고리 화합물 및 이를 유효성분으로 하는 항종양제 |
JP2000504134A JP4276376B2 (ja) | 1997-07-24 | 1998-07-24 | 複素環式化合物及びそれを有効成分とする抗腫瘍剤 |
AU83575/98A AU727013B2 (en) | 1997-07-24 | 1998-07-24 | Heterocyclic compound and antitumor agent comprising the same as effective component |
DK98933922T DK1020462T3 (da) | 1997-07-24 | 1998-07-24 | Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens |
DE69821633T DE69821633T2 (de) | 1997-07-24 | 1998-07-24 | Heterozyklische verbindungen und antitumormittel, das diese als aktiven wirkstoff enthält |
US09/463,214 US6251900B1 (en) | 1997-07-24 | 1998-07-24 | Heterocyclic compounds and antitumor agent containing the same as active ingredient |
CA002297326A CA2297326C (en) | 1997-07-24 | 1998-07-24 | Heterocyclic compound and antitumor agent containing the same as active component |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP19880497 | 1997-07-24 | ||
JP9/198804 | 1997-07-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999005138A1 true WO1999005138A1 (fr) | 1999-02-04 |
Family
ID=16397198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/003308 WO1999005138A1 (fr) | 1997-07-24 | 1998-07-24 | Composes heterocycliques et agent antitumoral contenant lesdits composes utilises comme ingredients actifs |
Country Status (11)
Country | Link |
---|---|
US (1) | US6251900B1 (ja) |
EP (1) | EP1020462B1 (ja) |
JP (1) | JP4276376B2 (ja) |
KR (1) | KR100563514B1 (ja) |
CN (1) | CN1129597C (ja) |
AU (1) | AU727013B2 (ja) |
CA (1) | CA2297326C (ja) |
DE (1) | DE69821633T2 (ja) |
DK (1) | DK1020462T3 (ja) |
ES (1) | ES2213286T3 (ja) |
WO (1) | WO1999005138A1 (ja) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000029404A1 (fr) * | 1998-11-17 | 2000-05-25 | Kumiai Chemical Industry Co., Ltd. | Derives de pyrimidinylbenzimidazole et de triazinylbenzimidazole et bactericides agricoles/horticoles |
WO2000043385A1 (fr) * | 1999-01-25 | 2000-07-27 | Zenyaku Kogyo Kabushiki Kaisha | Composes heterocycliques et agents antitumoraux les comprenant en tant que principe actif |
WO2000064880A1 (en) * | 1999-04-22 | 2000-11-02 | Synaptic Pharmaceutical Corporation | Selective npy (y5) antagonists |
US6214853B1 (en) | 1999-06-30 | 2001-04-10 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (bicyclics) |
US6218408B1 (en) | 1999-06-30 | 2001-04-17 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (bicyclics) |
US6222040B1 (en) | 1999-06-30 | 2001-04-24 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (tricyclics) |
US6225330B1 (en) | 1999-06-30 | 2001-05-01 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (tricyclics) |
US6340683B1 (en) * | 1999-04-22 | 2002-01-22 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (triazines) |
WO2002088112A1 (fr) * | 2001-04-27 | 2002-11-07 | Zenyaku Kogyo Kabushiki Kaisha | Compose heterocyclique et agent antitumoral contenant ce dernier en tant qu'ingredient actif |
US6943161B2 (en) * | 1999-12-28 | 2005-09-13 | Pharmacopela Drug Discovery, Inc. | Pyrimidine and triazine kinase inhibitors |
US6989379B1 (en) | 1999-04-22 | 2006-01-24 | H. Lundbick A/S | Selective NPY (Y5) antagonists |
JPWO2004037812A1 (ja) * | 2002-10-25 | 2006-02-23 | 全薬工業株式会社 | 複素環式化合物及びそれを有効成分とする抗腫瘍剤 |
US7273880B2 (en) | 1999-06-30 | 2007-09-25 | H. Lunbeck A/S | Selective NPY (Y5) antagonists |
WO2009066775A1 (ja) | 2007-11-22 | 2009-05-28 | Zenyaku Kogyo Kabushikikaisha | 複素環式化合物の非晶質体、それを含む固体分散体、薬剤、およびその製造法 |
US7750001B2 (en) | 2005-03-11 | 2010-07-06 | Zenyaku Kogyo Kabushikikaisha | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient |
JP2011522802A (ja) * | 2008-05-23 | 2011-08-04 | ワイス・エルエルシー | PI3キナーゼおよびmTOR阻害剤としてのトリアジン化合物 |
US8461158B2 (en) | 2009-03-27 | 2013-06-11 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
JP2013525419A (ja) * | 2010-04-30 | 2013-06-20 | ユニバーシティ・オブ・バーゼル | 抗増殖性障害の処置における使用のためのpi3k阻害剤としてのピペラジノトリアジン |
US8486939B2 (en) | 2009-07-07 | 2013-07-16 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
US9056852B2 (en) | 2011-03-28 | 2015-06-16 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US11304953B2 (en) | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
US11351176B2 (en) | 2017-08-14 | 2022-06-07 | Mei Pharma, Inc. | Combination therapy |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2316831B1 (en) * | 2002-11-21 | 2013-03-06 | Novartis AG | 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer |
US20050107374A1 (en) * | 2003-10-21 | 2005-05-19 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
CA2561406C (en) * | 2004-03-31 | 2012-07-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and anti-malignant-tumor agent comprising the same as effective component |
JP2008538544A (ja) * | 2004-09-23 | 2008-10-30 | レディ ユーエス セラピューティックス, インコーポレイテッド | 新規ピリミジン化合物、それらの調製のためのプロセスおよびそれらを含む組成物 |
JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
US20070244110A1 (en) * | 2006-04-14 | 2007-10-18 | Zenyaku Kogyo Kabushiki Kaisha | Treatment of prostate cancer, melanoma or hepatic cancer |
WO2008032033A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
US20090270390A1 (en) * | 2006-09-14 | 2009-10-29 | Astrazeneca | Pyrimidine derivatives |
WO2008032036A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
WO2008032091A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
WO2008032089A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
US20090233926A1 (en) * | 2006-09-14 | 2009-09-17 | Astrazeneca | 2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
WO2008032041A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives having inhibitory activity against pi3k enzymes |
AU2008213808B2 (en) * | 2007-02-06 | 2011-11-10 | Novartis Ag | PI 3-kinase inhibitors and methods of their use |
US8163748B2 (en) * | 2007-05-23 | 2012-04-24 | New York University | s-Triazine compounds, pharmaceutical compositions and method of using the same |
WO2009120094A2 (en) * | 2008-03-27 | 2009-10-01 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
US10022381B2 (en) | 2008-05-23 | 2018-07-17 | Pfizer Inc. | Triazine compounds as PI3 kinase and mTOR inhibitors |
WO2010012745A2 (en) * | 2008-07-29 | 2010-02-04 | Boehringer Ingelheim International Gmbh | Benzimidazoles |
KR20110120286A (ko) | 2009-02-12 | 2011-11-03 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로환 유도체 |
WO2010096619A1 (en) * | 2009-02-23 | 2010-08-26 | Wyeth Llc | Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
UA108390C2 (uk) | 2010-08-10 | 2015-04-27 | Астеллас Фарма Інк. | Похідні бензімідазолу та їх застосування |
CA2849995A1 (en) | 2011-09-27 | 2013-04-04 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
WO2014055647A1 (en) * | 2012-10-03 | 2014-04-10 | Mei Pharma, Inc. | (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
CN104245693B (zh) * | 2012-12-14 | 2016-08-24 | 上海恒瑞医药有限公司 | 嘧啶类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
JP6387360B2 (ja) | 2013-03-14 | 2018-09-05 | ノバルティス アーゲー | 変異idhの阻害薬としての3−ピリミジン−4−イル−オキサゾリジン−2−オン |
CN105175410B (zh) * | 2015-10-14 | 2018-01-05 | 湖南华腾制药有限公司 | 三嗪类化合物及其制备方法和抗肿瘤应用 |
CN112047938B (zh) * | 2019-06-06 | 2022-11-22 | 北京泰德制药股份有限公司 | 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06507643A (ja) * | 1991-05-01 | 1994-09-01 | ローヌ−プーラン ローラー インターナショナル (ホウルディングス) インコーポレイテッド | Egfおよび/又はpdgf受容体チロシンキナーゼを阻害するビスモノ−および二環式アリールおよびヘテロアリール化合物 |
JPH0948776A (ja) * | 1994-09-26 | 1997-02-18 | Dai Ichi Seiyaku Co Ltd | ピリミジニルピラゾール誘導体 |
-
1998
- 1998-07-24 US US09/463,214 patent/US6251900B1/en not_active Expired - Lifetime
- 1998-07-24 EP EP98933922A patent/EP1020462B1/en not_active Expired - Lifetime
- 1998-07-24 DE DE69821633T patent/DE69821633T2/de not_active Expired - Lifetime
- 1998-07-24 CA CA002297326A patent/CA2297326C/en not_active Expired - Fee Related
- 1998-07-24 WO PCT/JP1998/003308 patent/WO1999005138A1/ja active IP Right Grant
- 1998-07-24 ES ES98933922T patent/ES2213286T3/es not_active Expired - Lifetime
- 1998-07-24 JP JP2000504134A patent/JP4276376B2/ja not_active Expired - Fee Related
- 1998-07-24 AU AU83575/98A patent/AU727013B2/en not_active Ceased
- 1998-07-24 DK DK98933922T patent/DK1020462T3/da active
- 1998-07-24 CN CN98809385A patent/CN1129597C/zh not_active Expired - Fee Related
- 1998-07-24 KR KR1020007000424A patent/KR100563514B1/ko not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06507643A (ja) * | 1991-05-01 | 1994-09-01 | ローヌ−プーラン ローラー インターナショナル (ホウルディングス) インコーポレイテッド | Egfおよび/又はpdgf受容体チロシンキナーゼを阻害するビスモノ−および二環式アリールおよびヘテロアリール化合物 |
JPH0948776A (ja) * | 1994-09-26 | 1997-02-18 | Dai Ichi Seiyaku Co Ltd | ピリミジニルピラゾール誘導体 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1020462A4 * |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000029404A1 (fr) * | 1998-11-17 | 2000-05-25 | Kumiai Chemical Industry Co., Ltd. | Derives de pyrimidinylbenzimidazole et de triazinylbenzimidazole et bactericides agricoles/horticoles |
US6872729B2 (en) | 1998-11-17 | 2005-03-29 | Kumiai Chemical Industry Co., Ltd. | Pyrimidinylbenzimidazole and triazinylbenzimidazole derivatives and agricultural/horticultural fungicides |
US6576631B1 (en) | 1998-11-17 | 2003-06-10 | Kumiai Chemical Industry Co., Ltd. | Pyrimidinylbenzimidazole and triazinylbenzimidazole derivatives and agricultural/horticultural bactericides |
WO2000043385A1 (fr) * | 1999-01-25 | 2000-07-27 | Zenyaku Kogyo Kabushiki Kaisha | Composes heterocycliques et agents antitumoraux les comprenant en tant que principe actif |
AU775166B2 (en) * | 1999-04-22 | 2004-07-22 | H. Lundbeck A/S | Selective NPY (Y5) antagonists |
US6340683B1 (en) * | 1999-04-22 | 2002-01-22 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (triazines) |
US6569856B2 (en) | 1999-04-22 | 2003-05-27 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (triazines) |
US7189720B2 (en) | 1999-04-22 | 2007-03-13 | H. Lundbeck A/S | Selective NPY (Y5) antagonists |
WO2000064880A1 (en) * | 1999-04-22 | 2000-11-02 | Synaptic Pharmaceutical Corporation | Selective npy (y5) antagonists |
US6989379B1 (en) | 1999-04-22 | 2006-01-24 | H. Lundbick A/S | Selective NPY (Y5) antagonists |
US6222040B1 (en) | 1999-06-30 | 2001-04-24 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (tricyclics) |
US6225330B1 (en) | 1999-06-30 | 2001-05-01 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (tricyclics) |
US6218408B1 (en) | 1999-06-30 | 2001-04-17 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (bicyclics) |
US6214853B1 (en) | 1999-06-30 | 2001-04-10 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (bicyclics) |
US7273880B2 (en) | 1999-06-30 | 2007-09-25 | H. Lunbeck A/S | Selective NPY (Y5) antagonists |
US6943161B2 (en) * | 1999-12-28 | 2005-09-13 | Pharmacopela Drug Discovery, Inc. | Pyrimidine and triazine kinase inhibitors |
US7307077B2 (en) | 2001-04-27 | 2007-12-11 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as effective ingredient |
US7071189B2 (en) | 2001-04-27 | 2006-07-04 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
AU2002253619B2 (en) * | 2001-04-27 | 2007-05-17 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same active ingredients |
EP1389617A1 (en) * | 2001-04-27 | 2004-02-18 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
WO2002088112A1 (fr) * | 2001-04-27 | 2002-11-07 | Zenyaku Kogyo Kabushiki Kaisha | Compose heterocyclique et agent antitumoral contenant ce dernier en tant qu'ingredient actif |
EP1389617A4 (en) * | 2001-04-27 | 2006-03-29 | Zenyaku Kogyo Kk | Heterocyclic compound and antitumor agent containing it as an active ingredient |
KR101046015B1 (ko) | 2002-10-25 | 2011-07-01 | 젠야쿠코교가부시키가이샤 | 헤테로고리 화합물 및 이것을 유효성분으로 하는 항종양제 |
JPWO2004037812A1 (ja) * | 2002-10-25 | 2006-02-23 | 全薬工業株式会社 | 複素環式化合物及びそれを有効成分とする抗腫瘍剤 |
JP4493503B2 (ja) * | 2002-10-25 | 2010-06-30 | 全薬工業株式会社 | 複素環式化合物及びそれを有効成分とする抗腫瘍剤 |
US8338414B2 (en) | 2005-03-11 | 2012-12-25 | Zenyaku Kogyo Kabushikikaisha | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient |
JP5089377B2 (ja) * | 2005-03-11 | 2012-12-05 | 全薬工業株式会社 | 複素環式化合物を有効成分とする免疫抑制剤及び抗腫瘍剤 |
US7750001B2 (en) | 2005-03-11 | 2010-07-06 | Zenyaku Kogyo Kabushikikaisha | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient |
EP2409975A1 (en) | 2007-11-22 | 2012-01-25 | Zenyaku Kogyo Kabushikikaisha | Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same |
US8227463B2 (en) | 2007-11-22 | 2012-07-24 | Zenyaku Kogyo Kabushiki Kaisha | Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same |
WO2009066775A1 (ja) | 2007-11-22 | 2009-05-28 | Zenyaku Kogyo Kabushikikaisha | 複素環式化合物の非晶質体、それを含む固体分散体、薬剤、およびその製造法 |
KR101331341B1 (ko) | 2008-05-23 | 2013-11-19 | 와이어쓰 엘엘씨 | Pi3 키나제 및 mtor 억제제로서의 트리아진 화합물 |
JP2011522802A (ja) * | 2008-05-23 | 2011-08-04 | ワイス・エルエルシー | PI3キナーゼおよびmTOR阻害剤としてのトリアジン化合物 |
US9108980B2 (en) | 2009-03-27 | 2015-08-18 | Vetdc, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
US8772287B2 (en) | 2009-03-27 | 2014-07-08 | Vetdc, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
US8461158B2 (en) | 2009-03-27 | 2013-06-11 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
US8486939B2 (en) | 2009-07-07 | 2013-07-16 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
JP2013525419A (ja) * | 2010-04-30 | 2013-06-20 | ユニバーシティ・オブ・バーゼル | 抗増殖性障害の処置における使用のためのpi3k阻害剤としてのピペラジノトリアジン |
US9056852B2 (en) | 2011-03-28 | 2015-06-16 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US10064868B2 (en) | 2011-03-28 | 2018-09-04 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US10335415B2 (en) | 2011-03-28 | 2019-07-02 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US10603324B2 (en) | 2011-03-28 | 2020-03-31 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US11400097B2 (en) | 2011-03-28 | 2022-08-02 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US11304953B2 (en) | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
US11351176B2 (en) | 2017-08-14 | 2022-06-07 | Mei Pharma, Inc. | Combination therapy |
Also Published As
Publication number | Publication date |
---|---|
EP1020462A4 (en) | 2003-01-08 |
DE69821633D1 (de) | 2004-03-18 |
KR20010021860A (ko) | 2001-03-15 |
CN1129597C (zh) | 2003-12-03 |
EP1020462B1 (en) | 2004-02-11 |
DK1020462T3 (da) | 2004-04-26 |
JP4276376B2 (ja) | 2009-06-10 |
AU727013B2 (en) | 2000-11-30 |
DE69821633T2 (de) | 2004-12-16 |
ES2213286T3 (es) | 2004-08-16 |
EP1020462A1 (en) | 2000-07-19 |
CA2297326C (en) | 2007-03-20 |
KR100563514B1 (ko) | 2006-03-27 |
CA2297326A1 (en) | 1999-02-04 |
CN1271355A (zh) | 2000-10-25 |
US6251900B1 (en) | 2001-06-26 |
AU8357598A (en) | 1999-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999005138A1 (fr) | Composes heterocycliques et agent antitumoral contenant lesdits composes utilises comme ingredients actifs | |
EP1389617B1 (en) | Heterocyclic compound and antitumor agent containing the same as active ingredient | |
US7671063B2 (en) | 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors | |
AU2003275630B2 (en) | Heterocyclic compounds and antitumor agent comprising the same as effective component | |
EP1373253B1 (en) | Inhibitors of cyclin dependent kinases as anti-cancer agent | |
EP1741714B1 (en) | Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient | |
US20100168182A1 (en) | Compounds and compositions as kinase inhibitors | |
IL155618A (en) | Derivatives of indolyl malayamide as inhibitors of protein-kinase C | |
WO2000043385A1 (fr) | Composes heterocycliques et agents antitumoraux les comprenant en tant que principe actif | |
JPH04235983A (ja) | 新規キノリン誘導体およびそれを有効成分として含有する制癌剤効果増強剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98809385.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020007000424 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 83575/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998933922 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2297326 Country of ref document: CA Ref document number: 2297326 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09463214 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998933922 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 83575/98 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007000424 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998933922 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007000424 Country of ref document: KR |